Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$31.82 USD
-10.78 (-25.31%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $31.81 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Arcturus Therapeutics Holdings Inc. [ARCT]
Reports for Purchase
Showing records 121 - 140 ( 140 total )
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
2Q Recap: The Story Is Beginning to Gain Traction
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Another Key Collaboration Expansion as Institutional Investors Step in; Raise PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Lead drug ARCT-810 Granted Orphan Drug Designation
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Why Attend and Who to See at Our ROTH RNA Revolution Conference on July 17?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Save a Seat at Our RNA Revolution Conference on July 17 in NY
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Substantial Expansion of Ultragenyx Collaboration Adds Cash and Validation; Raise PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare -Recap of Our 27 Most Valuable Industry Notes in 2019
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Expecting Additional Insights on ARCT-810 and LUNAR Platform in 2019 Annual Meeting of TIDES; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q19 - More Partnership Branches to Sprout Off the Tree
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Recap; Steady as She Goes; OTC Remains the Focus
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
The Bright Red Giant Star; Initiating Buy, $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Geno-dome: I.V. mRNA and Safety - What to Look For?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Part 2 - Which Orphan Companies to See and Why at Our 31st ROTH Conference?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Arcturus Therapeutics Holdings Inc.
Industry: Medical - Biomedical and Genetics
Hidden Gem in the mRNA Crowd; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y